CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to GILD

Sacituzumab Govitecan-Hziy plus bevacizumab

Phase 2
Gilead Sciences, Inc. (GILD)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '26
GILDPhase 2

Sacituzumab Govitecan-Hziy plus bevacizumab Phase 2 Est. Readout

Sacituzumab Govitecan-Hziy plus bevacizumab
Nov 2026~
CT.gov
00%
Competitive Landscape

0 competitors in NSCLC Stage IV

View Full Landscape
Drug Information

Target Indication

NSCLC Stage IV

Clinical Trial

NCT06401824

Last updated: 10/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.